Erythromycin is a macrolide antibiotic with a primarily bacteriostatic action against a broad range of bacteria. It is generally well tolerated and only rarely causes serious adverse effects. However, it has a stimulant activity on the gut, and gastrointestinal disturbances such as abdominal discomfort, nausea, vomiting, and diarrhoea tend to occur after both oral and parenteral administration. These gastrointestinal side effects are dose related and are more common in younger than in older subjects.' It was the first of the macrolide antibiotics to be used for the treatment of infections and there are now more than 40 years' experience of use with the drug.2 Initially it was used primarily against Gram positive cocci such as pneumococci, streptococci, and staphylococci, and was of particular use in the treatment of these infections in patients allergic to penicillin. This remained the place of erythromycin for some years, but in the last 20 years or so, and particularly in the last 10 years, there has been a significant increase in the prescription of the drug.
Between 1980 and 1990 there was a 30% increase in total antibiotic prescriptions in England.3 During this period the prescriptions for erythromycin increased by 72% ( figure) ; there was also a significant increase in the prescription for broad spectrum penicillins (45%) and cephalosporin antibiotics (50%). Over the same period prescriptions for the sulphonamides and trimethoprim remained almost static, whereas tetracycline prescriptions fell by 43% spectrum penicillins accounting for over 60%. Data from other countries show a similar change in the pattern of prescriptions. In 1988 erythromycin accounted for 15% of total antibiotic prescriptions in Finland, with a threefold increase having taken place over the previous 10 years. 4 It is interesting to study the reasons for this increase in the use of erythromycin.
Indications for erythromycin Its main use is in the treatment of upper and lower respiratory tract infections and in various skin and soft tissue infections. It is also useful in pertussis, Lyme disease, toxoplasmosis, and in Campylobacter infections, and has a place in certain sexually transmitted diseases. There are no data as to the type of infection for which prescriptions are issued, but it can be assumed that a large proportion are for respiratory infections. The increase is probably partly due to the recognition of its efficacy in the treatment of atypical infections caused by mycoplasmas and chlamydia, but interest was also stimulated by the recognition of its activity against Legionnaires' disease.6 Legionella pneumophila was first isolated in 1976 and erythromycin is considered to be the drug of choice. Its effect on Mycoplasma pneumoniae was first reported in the late 1960s,7 and it was later shown that erythromycin has about the same antichlamydial activity as tetracycline.
Studies of the aetiology of community acquired respiratory infections have shown the importance of the atypical organisms as causes of pneumonia and milder respiratory infection, and this has stimulated the use of erythromycin in community acquired infections. There has been some discrepancy in estimates of the frequency of mycoplasma, chlamydia, and legionella as causes of community acquired infection,8'2 probably because some studies have looked at the incidence over one year while others have looked at the pattern over several years. The cyclical variation in the incidence of mycoplasma infections, with epidemics occurring every three or four years, is well known, but outbreaks of legionella infection have also appeared from time to time and this initially led to an overestimate of its importance as a pathogen. Taking into account these variations, it does appear that the atypical infections, for which erythromycin would be the drug of choice, occur in about 10% of community acquired infections. Tetracyclines remain the drug of choice in chlamydial and probably rickettsial infections, but the problems of tetracyclines in children and pregnant women have led to the more routine use of erythromycin.
Since the antimicrobial spectrum of erythromycin includes activity against pneumococci, and since these are the commonest cause of community acquired pneumonia, some physicians have advocated its routine use in community acquired infection. Used alone it may well be inadequate for some infections -for example, it will be less effective in bacteraemic illness because of the relatively poor serum levels and this would be of particular concern in severe pneumococcal infection with bacteraemia. There is also concern about increasing resistance of Streptococcus pneumoniae to erythromycin. The Erythromycin or any other macrolide should also form part of the initial antibiotic regimen in all patients with severe or life threatening illness, and in these patients it should be given intravenously in the first instance.
Improved knowledge of the type of pathogens responsible for community acquired infections has been of help in producing guidelines on the antibiotic treatment of pneumonia. ' 
